Symbols / ENLV $1.04 -2.80%
ENLV Chart
About
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 246.88M |
| Enterprise Value | 7.76M | Income | -12.70M | Sales | — |
| Book/sh | 0.72 | Cash/sh | 0.75 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -3.25 | PEG | — |
| P/S | — | P/B | 1.44 | P/C | — |
| EV/EBITDA | -0.54 | EV/Sales | — | Quick Ratio | 6.26 |
| Current Ratio | 6.43 | Debt/Eq | 4.01 | LT Debt/Eq | — |
| EPS (ttm) | -0.54 | EPS next Y | -0.32 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 16:00 | ROA | -36.02% |
| ROE | -57.64% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 237.38M |
| Shs Float | 6.28M | Short Float | 0.24% | Short Ratio | 1.66 |
| Short Interest | — | 52W High | 2.10 | 52W Low | 0.66 |
| Beta | 1.64 | Avg Volume | 395.83K | Volume | 105.93K |
| Target Price | $13.00 | Recom | None | Prev Close | $1.07 |
| Price | $1.04 | Change | -2.80% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$13.00
Mean price target
2. Current target
$1.04
Latest analyst target
3. DCF / Fair value
$-0.42
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.04
Low
$13.00
High
$13.00
Mean
$13.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-12 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2025-11-24 | down | D. Boral Capital | Buy → Hold | — |
| 2025-10-29 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-09-26 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-09-12 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-09-02 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-08-22 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-08-18 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-07-29 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-07-22 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-04-21 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-04-03 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-03-24 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-03-03 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-02-07 | main | D. Boral Capital | Buy → Buy | $13 |
| 2024-12-11 | main | D. Boral Capital | Buy → Buy | $13 |
| 2024-12-03 | main | D. Boral Capital | Buy → Buy | $13 |
| 2024-11-14 | main | D. Boral Capital | Buy → Buy | $13 |
| 2024-09-27 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-09-26 | main | EF Hutton | Buy → Buy | $13 |
- Enlivex (Nasdaq: ENLV) raises $212M to launch RAIN prediction markets treasury plan - Stock Titan Mon, 24 Nov 2025 08
- EXCLUSIVE: Enlivex Raises Over $200 Million To Launch First Public Company Prediction Markets Play - Yahoo Finance Mon, 24 Nov 2025 08
- ENLV Stock Surges After Pivot To Crypto-Backed Treasury, Names Former Italian PM To Board - Stocktwits Fri, 21 Nov 2025 08
- Enlivex: A Necessary Update - This Is No Longer The Company We Covered In 2022 (NASDAQ:ENLV) - Seeking Alpha Sat, 13 Dec 2025 08
- Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation - simplywall.st ue, 07 Oct 2025 07
- Enlivex Ltd.: Performance & Quotes, ENLV Stock Price on Nasdaq Exchange - marketscreener.com Wed, 25 Feb 2026 04
- New Analyst Forecast: $ENLV Given $13.0 Price Target - Nasdaq ue, 22 Jul 2025 07
- Enlivex Therapeutics Ltd. (ENLV) Stock: Soars After $212M Bet on RAIN Crypto Strategy - CoinCentral Mon, 24 Nov 2025 08
- New Analyst Forecast: $ENLV Given $13 Price Target | ENLV Stock News - Quiver Quantitative Mon, 12 Jan 2026 08
- ENLV: Analyst Raises Price Target Significantly | ENLV Stock New - GuruFocus Mon, 12 Jan 2026 08
- Enlivex (ENLV) Stock Analysis Report | Financials & Insights - Benzinga Japan Wed, 25 Feb 2026 07
- Enlivex Therapeutics (NASDAQ:ENLV) Rating Increased to Hold at Wall Street Zen - MarketBeat Sat, 28 Feb 2026 07
- Enlivex Ltd. (ENLV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Mon, 24 Nov 2025 15
- Biotech Enlivex shifts share trading to Nasdaq, leaves Tel Aviv in April - Stock Titan Fri, 23 Jan 2026 08
- Enlivex Therapeutics (NASDAQ: ENLV) prices $212M PIPE and adds Matteo Renzi to board - Stock Titan Mon, 24 Nov 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -13.25M | -18.85M | -18.94M | -23.77M |
| TotalUnusualItems | -1.14M | -5.47M | -6.08M | 5.03M |
| TotalUnusualItemsExcludingGoodwill | -1.14M | -5.47M | -6.08M | 5.03M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -15.01M | -29.07M | -31.06M | -14.47M |
| ReconciledDepreciation | 545.00K | 835.00K | 777.00K | 546.00K |
| EBITDA | -14.39M | -24.32M | -25.02M | -18.74M |
| EBIT | -14.93M | -25.15M | -25.80M | -19.29M |
| NetInterestIncome | 1.06M | 1.55M | 821.00K | -208.00K |
| InterestIncome | 1.07M | 1.56M | 835.00K | 120.00K |
| NormalizedIncome | -13.88M | -23.60M | -24.98M | -19.50M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -15.01M | -29.07M | -31.06M | -14.47M |
| TotalExpenses | 14.93M | 25.15M | 25.80M | 19.29M |
| TotalOperatingIncomeAsReported | -15.89M | -29.39M | -25.80M | -19.29M |
| DilutedAverageShares | 20.51M | 18.57M | 18.39M | 17.86M |
| BasicAverageShares | 20.51M | 18.57M | 18.39M | 17.86M |
| DilutedEPS | -0.73 | -1.56 | -1.69 | -0.81 |
| BasicEPS | -0.73 | -1.56 | -1.69 | -0.81 |
| DilutedNIAvailtoComStockholders | -15.01M | -29.07M | -31.06M | -14.47M |
| NetIncomeCommonStockholders | -15.01M | -29.07M | -31.06M | -14.47M |
| NetIncome | -15.01M | -29.07M | -31.06M | -14.47M |
| NetIncomeIncludingNoncontrollingInterests | -15.01M | -29.07M | -31.06M | -14.47M |
| NetIncomeContinuousOperations | -15.01M | -29.07M | -31.06M | -14.47M |
| PretaxIncome | -15.01M | -29.07M | -31.06M | -14.47M |
| OtherIncomeExpense | -1.14M | -5.47M | -6.08M | 5.03M |
| SpecialIncomeCharges | -957.00K | -4.24M | 0.00 | 0.00 |
| GainOnSaleOfPPE | -957.00K | -4.24M | 0.00 | 0.00 |
| GainOnSaleOfSecurity | -182.00K | -1.22M | -6.08M | 5.03M |
| NetNonOperatingInterestIncomeExpense | 1.06M | 1.55M | 821.00K | -208.00K |
| TotalOtherFinanceCost | 13.00K | 14.00K | 14.00K | 328.00K |
| InterestIncomeNonOperating | 1.07M | 1.56M | 835.00K | 120.00K |
| OperatingIncome | -14.93M | -25.15M | -25.80M | -19.29M |
| OperatingExpense | 14.93M | 25.15M | 25.80M | 19.29M |
| OtherOperatingExpenses | 105.00K | 906.00K | 402.00K | 167.00K |
| OtherTaxes | -605.00K | 0.00 | 0.00 | |
| ResearchAndDevelopment | 10.62M | 19.01M | 18.69M | 12.88M |
| SellingGeneralAndAdministration | 4.81M | 5.23M | 6.70M | 6.24M |
| GeneralAndAdministrativeExpense | 4.81M | 5.23M | 6.70M | 6.24M |
| OtherGandA | 1.26M | 1.44M | 2.00M | 1.45M |
| InsuranceAndClaims | 351.00K | 567.00K | 895.00K | 783.00K |
| SalariesAndWages | 3.20M | 3.23M | 3.81M | 4.01M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 23.65M | 18.60M | 18.42M | 18.33M |
| ShareIssued | 23.65M | 18.60M | 18.42M | 18.33M |
| TotalDebt | 534.00K | 1.03M | 4.85M | 6.01M |
| TangibleBookValue | 23.59M | 30.08M | 56.84M | 85.04M |
| InvestedCapital | 23.59M | 30.08M | 56.84M | 85.04M |
| WorkingCapital | 22.19M | 27.70M | 45.72M | 81.72M |
| NetTangibleAssets | 23.59M | 30.08M | 56.84M | 85.04M |
| CapitalLeaseObligations | 534.00K | 1.03M | 4.85M | 6.01M |
| CommonStockEquity | 23.59M | 30.08M | 56.84M | 85.04M |
| TotalCapitalization | 23.59M | 30.08M | 56.84M | 85.04M |
| TotalEquityGrossMinorityInterest | 23.59M | 30.08M | 56.84M | 85.04M |
| StockholdersEquity | 23.59M | 30.08M | 56.84M | 85.04M |
| GainsLossesNotAffectingRetainedEarnings | 1.10M | 1.10M | 1.10M | 1.10M |
| OtherEquityAdjustments | 1.10M | 1.10M | ||
| ForeignCurrencyTranslationAdjustments | 1.10M | 1.10M | 1.10M | |
| RetainedEarnings | -127.11M | -112.09M | -83.03M | -51.97M |
| AdditionalPaidInCapital | 146.91M | 138.94M | 136.65M | 133.80M |
| CapitalStock | 2.69M | 2.14M | 2.12M | 2.11M |
| CommonStock | 2.69M | 2.14M | 2.12M | 2.11M |
| TotalLiabilitiesNetMinorityInterest | 4.10M | 6.75M | 10.80M | 10.11M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 299.00K | 686.00K | 4.19M | 5.39M |
| OtherNonCurrentLiabilities | 5.39M | |||
| LongTermDebtAndCapitalLeaseObligation | 299.00K | 686.00K | 4.19M | 5.39M |
| LongTermCapitalLeaseObligation | 299.00K | 686.00K | 4.19M | 5.39M |
| CurrentLiabilities | 3.80M | 6.06M | 6.61M | 4.72M |
| OtherCurrentLiabilities | 142.00K | 1.23M | ||
| CurrentDebtAndCapitalLeaseObligation | 235.00K | 346.00K | 653.00K | 617.00K |
| CurrentCapitalLeaseObligation | 235.00K | 346.00K | 653.00K | 617.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.41M | 889.00K | 759.00K | 1.07M |
| PayablesAndAccruedExpenses | 2.02M | 3.59M | 5.20M | 3.03M |
| CurrentAccruedExpenses | 1.20M | 2.77M | 3.25M | 2.15M |
| Payables | 811.00K | 827.00K | 1.95M | 878.00K |
| DuetoRelatedPartiesCurrent | 113.00K | |||
| AccountsPayable | 811.00K | 827.00K | 1.95M | 878.00K |
| TotalAssets | 27.69M | 36.83M | 67.64M | 95.15M |
| TotalNonCurrentAssets | 1.69M | 3.07M | 15.31M | 8.70M |
| OtherNonCurrentAssets | 317.00K | 300.00K | 299.00K | 321.00K |
| NonCurrentPrepaidAssets | 18.00K | 187.00K | 113.00K | 164.00K |
| NonCurrentAccountsReceivable | 206.00K | |||
| InvestmentsAndAdvances | 3.00K | |||
| OtherInvestments | 3.00K | |||
| NetPPE | 1.15M | 2.58M | 14.90M | 8.22M |
| AccumulatedDepreciation | -3.65M | -3.99M | -3.53M | -1.97M |
| GrossPPE | 4.80M | 6.57M | 18.43M | 10.19M |
| Leases | 947.00K | 1.43M | 8.61M | 1.52M |
| OtherProperties | 3.27M | 4.55M | 9.30M | 8.22M |
| MachineryFurnitureEquipment | 586.00K | 591.00K | 525.00K | 448.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 25.99M | 33.76M | 52.33M | 86.44M |
| AssetsHeldForSaleCurrent | 198.00K | 5.11M | 0.00 | |
| RestrictedCash | 113.00K | 113.00K | ||
| PrepaidAssets | 884.00K | 1.11M | 1.44M | 1.11M |
| Receivables | 1.42M | 229.00K | 647.00K | 1.09M |
| OtherReceivables | 1.35M | 113.00K | 125.00K | 14.00K |
| TaxesReceivable | 68.00K | 116.00K | 522.00K | 1.07M |
| AccountsReceivable | 2.20M | |||
| CashCashEquivalentsAndShortTermInvestments | 23.50M | 27.32M | 50.24M | 84.13M |
| OtherShortTermInvestments | 20.20M | 26.51M | 299.00K | 72.93M |
| CashAndCashEquivalents | 3.30M | 813.00K | 49.95M | 11.20M |
| CashEquivalents | 1.04M | 0.00 | 47.82M | 10.00M |
| CashFinancial | 2.26M | 813.00K | 2.12M | 1.20M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -13.11M | -23.76M | -32.08M | -19.17M |
| IssuanceOfCapitalStock | 6.45M | 360.00K | 0.00 | 53.17M |
| CapitalExpenditure | -103.00K | -236.00K | -8.12M | -1.62M |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 3.73M | 1.23M | 50.36M | 11.64M |
| BeginningCashPosition | 1.23M | 50.36M | 11.64M | 7.01M |
| EffectOfExchangeRateChanges | 0.00 | 0.00 | -408.00K | |
| ChangesInCash | 2.50M | -49.13M | 38.72M | 5.03M |
| FinancingCashFlow | 6.45M | 360.00K | 150.00K | 60.98M |
| CashFlowFromContinuingFinancingActivities | 6.45M | 360.00K | 150.00K | 60.98M |
| ProceedsFromStockOptionExercised | 2.00K | 0.00 | 150.00K | 7.81M |
| NetCommonStockIssuance | 6.45M | 360.00K | 0.00 | 53.17M |
| CommonStockIssuance | 6.45M | 360.00K | 0.00 | 53.17M |
| InvestingCashFlow | 9.06M | -25.97M | 62.52M | -38.41M |
| CashFlowFromContinuingInvestingActivities | 9.06M | -25.97M | 62.52M | -38.41M |
| NetInvestmentPurchaseAndSale | 8.98M | -25.86M | 70.65M | -36.78M |
| SaleOfInvestment | 41.35M | 301.00K | 72.55M | 67.63M |
| PurchaseOfInvestment | -32.37M | -26.17M | -1.91M | -104.42M |
| NetPPEPurchaseAndSale | 81.00K | -103.00K | -8.12M | -1.62M |
| SaleOfPPE | 184.00K | 133.00K | 0.00 | 0.00 |
| PurchaseOfPPE | -103.00K | -236.00K | -8.12M | -1.62M |
| OperatingCashFlow | -13.01M | -23.52M | -23.95M | -17.54M |
| CashFlowFromContinuingOperatingActivities | -13.01M | -23.52M | -23.95M | -17.54M |
| ChangeInWorkingCapital | -1.22M | -1.82M | 804.00K | -1.36M |
| ChangeInOtherCurrentLiabilities | -591.00K | -955.00K | -1.33M | -84.00K |
| ChangeInPayablesAndAccruedExpense | -1.06M | -1.47M | 1.85M | -24.00K |
| ChangeInAccruedExpense | -1.04M | -350.00K | 684.00K | -466.00K |
| ChangeInPayable | -16.00K | -1.12M | 1.17M | 442.00K |
| ChangeInAccountPayable | -16.00K | -1.12M | 1.17M | 442.00K |
| ChangeInPrepaidAssets | 433.00K | 608.00K | 278.00K | -1.25M |
| OtherNonCashItems | 297.00K | 696.00K | 831.00K | 413.00K |
| StockBasedCompensation | 2.06M | 1.95M | 2.71M | 2.91M |
| DepreciationAmortizationDepletion | 545.00K | 835.00K | 777.00K | 546.00K |
| DepreciationAndAmortization | 545.00K | 835.00K | 777.00K | 546.00K |
| Depreciation | 545.00K | 835.00K | 777.00K | 546.00K |
| OperatingGainsLosses | 317.00K | 3.88M | 1.98M | -5.59M |
| PensionAndEmployeeBenefitExpense | 0.00 | |||
| GainLossOnInvestmentSecurities | -558.00K | -343.00K | 1.98M | -5.59M |
| GainLossOnSaleOfPPE | -82.00K | -20.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -15.01M | -29.07M | -31.06M | -14.47M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for ENLV
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|